Drug intelligence / Profile preview

propofol + fentanyl + ketamine

Development stage: Unknown
Lead developer: The University of Jordan
Modality: Small Molecules
Administration: Intravenous

Overview

**Propofol + fentanyl + ketamine** is an intravenous procedural-sedation and analgesia regimen evaluated as an alternative to general anesthesia for endoscopic procedures and minor urological surgery. Propofol enhances inhibitory gamma-aminobutyric acid type A receptor signaling to produce rapid sedation and hypnosis, fentanyl is a potent mu-type opioid receptor agonist that provides analgesia, and ketamine is a noncompetitive N-methyl-D-aspartate receptor antagonist that provides dissociative anesthesia and analgesia. The combination is intended to achieve deep sedation with analgesia while potentially avoiding some requirements and risks of general anesthesia.

Other names: PFK

Targets

PFKFB3

Beyond the preview

Go deeper on propofol + fentanyl + ketamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + fentanyl + ketamine.

Explore the full profile